Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1109720

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which drugs has his Department identified as at risk of shortage in the event that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241075
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241073 241074 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109719

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nervous System: Pain
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with representatives of the NHS on the availability of drugs to treat neuropathic pain in the event that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241074
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241073 241075 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109718

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with representatives of the NHS on the availability of drugs to treat epilepsy in the event of that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241073
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241074 241075 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West